Stifel Nicolaus Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $32.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target dropped by equities research analysts at Stifel Nicolaus from $36.00 to $32.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 159.32% from the stock’s current price.

A number of other analysts have also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price target on shares of Zentalis Pharmaceuticals in a research report on Wednesday, February 28th. Wedbush boosted their price target on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $38.00.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL traded up $0.03 during mid-day trading on Wednesday, hitting $12.34. 154,808 shares of the stock traded hands, compared to its average volume of 773,694. Zentalis Pharmaceuticals has a twelve month low of $9.56 and a twelve month high of $31.46. The firm has a 50 day simple moving average of $13.76 and a two-hundred day simple moving average of $13.43. The company has a market cap of $876.26 million, a PE ratio of -2.71 and a beta of 1.82.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.91. The business had revenue of $40.56 million during the quarter, compared to the consensus estimate of $35.00 million. During the same quarter last year, the business earned ($1.07) EPS. On average, equities research analysts anticipate that Zentalis Pharmaceuticals will post -3.72 earnings per share for the current fiscal year.

Insider Activity

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of Zentalis Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $11.44, for a total transaction of $29,435.12. Following the completion of the transaction, the chief financial officer now owns 451,449 shares in the company, valued at approximately $5,164,576.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its position in shares of Zentalis Pharmaceuticals by 132.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock valued at $36,000 after purchasing an additional 1,030 shares during the last quarter. Quest Partners LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth approximately $38,000. Tower Research Capital LLC TRC grew its holdings in Zentalis Pharmaceuticals by 252.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after purchasing an additional 2,589 shares during the period. Exchange Traded Concepts LLC increased its position in Zentalis Pharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock worth $91,000 after buying an additional 1,519 shares during the last quarter. Finally, OneAscent Financial Services LLC bought a new position in shares of Zentalis Pharmaceuticals during the 4th quarter worth $156,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.